The University of Chicago Header Logo

Connection

Jessica Donington to Immunotherapy

Back to Details
This is a "connection" page, showing publications Jessica Donington has written about Immunotherapy.
Jessica Donington
Connection Strength
0.857
Immunotherapy
  1. Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors. Thorac Surg Clin. 2023 May; 33(2):189-196.
    View in: PubMed
    Score: 0.154
  2. Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.
    View in: PubMed
    Score: 0.150
  3. Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care. Ann Surg Oncol. 2022 09; 29(9):5344-5346.
    View in: PubMed
    Score: 0.146
  4. Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 02 20; 40(6):530-538.
    View in: PubMed
    Score: 0.142
  5. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.140
  6. Commentary: Why does neoadjuvant therapy suddenly make sense for early stage non-small cell lung cancer? J Thorac Cardiovasc Surg. 2020 11; 160(5):1383-1384.
    View in: PubMed
    Score: 0.126
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.